Skip to main content
. Author manuscript; available in PMC: 2021 Jul 14.
Published in final edited form as: Immunity. 2020 Jun 17;53(1):106–114.e5. doi: 10.1016/j.immuni.2020.06.007

Figure 5. Disruption of the hCASP1-mGSDMD interface compromises pyroptosis.

Figure 5.

(A) LDH release upon expression of wild type or mutant mGSDMD along with wild type hCASP1 catalytic domain (p22/p10) in HEK293T cells at 6, 8 or 10 hours post-transfection is plotted as a percentage of total LDH content upon 1% Triton X-100 treatment of the cells. Data shown are mean ± SD of three independent experiments.

(B) Upper panel: LDH release upon expression of wild type or mutant mGSDMD in GSDMD deficient THP-1 cells upon stimulation with nigericin for 0.5, 1.0, 1.5 and 2.0 hr. Data shown are mean ± standard deviation (SD) of three independent experiments. Lower panel: Propidium iodide uptake by the same cells as the upper panel 1.0 hr post nigericin treatment. Data shown are representative of three independent experiments.

(C) LDH release upon expression of wild type or mutant hCASP1 catalytic domain (p22/p10) along with wild type mGSDMD in HEK293T cells at 6, 8 or 10 hours post-transfection is plotted as a percentage of total LDH content upon 1% Triton X-100 treatment of the cells. Data shown are mean ± SD of three independent experiments.

See also Figure S5.